<bill session="117" type="s" number="3394" updated="2022-12-30T03:34:01Z">
  <state datetime="2021-12-14">REFERRED</state>
  <status>
    <introduced datetime="2021-12-14"/>
  </status>
  <introduced datetime="2021-12-14"/>
  <titles>
    <title type="display">Emergency Use Transparency Act</title>
    <title type="short" as="introduced">Emergency Use Transparency Act</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to emergency use authorization transparency.</title>
  </titles>
  <sponsor bioguide_id="H001076"/>
  <cosponsors>
    <cosponsor bioguide_id="B001310" joined="2021-12-14"/>
    <cosponsor bioguide_id="M001153" joined="2021-12-14"/>
  </cosponsors>
  <actions>
    <action datetime="2021-12-14">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-12-14" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="3799" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Emergency medical services and trauma care"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government information and archives"/>
    <term name="Health technology, devices, supplies"/>
  </subjects>
  <amendments/>
  <summary date="2022-07-26T18:36:18Z" status="Introduced in Senate">Emergency Use Transparency Act

This bill expands existing statutory provisions requiring the Food and Drug Administration (FDA) to publish notices of authorizations, terminations, or revocations of emergency use authorizations for medical products.

Specifically, the bill requires the FDA to publish such notices on its website. The bill also allows the FDA's disclosures to include a summary of data or information from additional types of submissions.</summary>
</bill>
